



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 227-135

C# M#

TÄHTINEN et al

Group Art Unit: 1648

Serial No. 09/622,976

Examiner: A. R. salimi

Filed: October 6, 2000

Date: January 21, 2003

Title: SELF-REPLICATING VECTOR FOR DNA IMMUNIZATION AGAINST HIV

RECEIVED

JAN 24 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**AMENDMENT UNDER 37 CFR § 1.111**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☒ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment 15 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 1 minus highest number  
previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this  
paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months) \$ 930.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

**Subtotal \$ 930.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: **COPY OF NOTICE TO COMPLY WITH REQUIREMENTS AND PAPER AND COMPUTER  
READABLE FORM OF THE SEQUENCE LISTING ALONG WITH FLOPPY DISKETTE** 0.00

**TOTAL FEE ENCLOSED \$ 930.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
GRT:ap

NIXON & VANDERHYE P.C.  
By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature: 



RECEIVED

JAN 24 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/290

In re Patent Application of

TÄHTINEN et al.

Atty. Ref.: 227-135

Appln. No. 09/622,976

Group Art Unit: 1648

Filed: October 6, 2000

Examiner: A.R. Salimi

FOR: SELF-REPLICATING VECTOR FOR DNA IMMUNIZATION AGAINST HIV

#9  
Amend. B w/ ext.  
Seq. List. (Zones)  
1/28/03

\* \* \*

AMENDMENT UNDER 37 CFR § 1.111

Tuesday, January 21, 2003  
(Monday = Federal Holiday)

Hon. Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the pending Office Action (Paper No. 7) mailed July 18, 2002, entry and consideration of the following amendments and remarks are respectfully requested.

IN THE SPECIFICATION

Kindly enter the following amended paragraphs.

Page 11, third paragraph starting at line 13:

Phase 1:

The HIV-1 REV (SEQ ID NO:2) and TAT (SEQ ID NO:3) genes from isolate BRU also called LAI (SEQ ID NO:4) (Wain-Hobson et al. Cell 40:9-17, 1985) were amplified from the pcREV and pcTAT vectors (Arya et al. Science 229:69-73, 1985) using Dynazyme Taq DNA polymerase (Finnzymes, Finland) and the following primers that have restriction enzyme sites for enzymes XhoI and XbaI:

Page 11, fourth paragraph starting at line 20: ✓

For REV:

5'-TTTTTCTAGAACCATGGCAGGAAGAAGCGGA-3' (SEQ ID NO:5)

5'-TTTTCTCGAGCTATTCTTTAGTTCCTGG-3' (SEQ ID NO:6)

01/23/2003 HBLANCO 00000006 09622976

930.00 DP

01 FC:1253

70154